Cargando…
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
BACKGROUND: Reduction in elevated serum cholesterol concentrations is important in the management of individuals at risk of atherosclerotic cardiovascular disease (ASCVD), such as myocardial infarction and thrombotic stroke. Although HMGCoA reductase inhibitors (“statins”) are frequently used for th...
Autores principales: | Di Bisceglie, Adrian M., Watts, Gerald F., Lavin, Philip, Yu, Meng, Bai, Ru, Liu, Liping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661247/ https://www.ncbi.nlm.nih.gov/pubmed/33183320 http://dx.doi.org/10.1186/s12944-020-01406-4 |
Ejemplares similares
-
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
por: Harrison, Stephen A., et al.
Publicado: (2021) -
Efficacy Evaluation of 10-Hydroxy Chondrofoline and Tafenoquine against Leishmania tropica (HTD(7))
por: Shah, Sayyed Ibrahim, et al.
Publicado: (2022) -
Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine
por: Wang, Yan, et al.
Publicado: (2017) -
Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review
por: Koppen, Laura M., et al.
Publicado: (2017) -
Htd2 deficiency-associated suppression of α-lipoic acid production provokes mitochondrial dysfunction and insulin resistance in adipocytes
por: Zeng, Mengqi, et al.
Publicado: (2021)